Antibiotic use in cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Chronic pulmonary infections significantly increase morbidity and mortality in cystic fibrosis (CF) patients.
• Pseudomonas aeruginosa (PA), Staphylococcus aureus, and Hemophilus influenzae are primary CF pathogens.
• Altered pharmacokinetic variables of antibiotics are reported in CF patients.

Purpose of the Study:

• To review current antibiotic therapies for pulmonary infections in CF.
• To discuss challenges in treating chronic PA infections.
• To highlight ongoing questions regarding optimal antibiotic dosing and duration.

Main Methods:

• Literature review of antibiotic therapy in CF pulmonary infections.
• Analysis of common pathogens and their sensitivities.
• Evaluation of treatment outcomes for acute and chronic infections.

Main Results:

• Intravenous antibiotic combinations, particularly broad-spectrum penicillin and aminoglycosides, show efficacy for acute exacerbations.
• Prophylactic antibiotics can be effective when pathogens are sensitive.
• Effective oral agents for chronic PA infections are lacking, and aerosolized antibiotics offer no advantage over systemic therapy for acute issues.

Conclusions:

• Current intravenous antibiotic regimens are the mainstay for acute CF pulmonary exacerbations.
• Effective management of chronic Pseudomonas aeruginosa infections remains a significant challenge.
• Further research is needed to determine optimal antibiotic dosages, frequencies, and treatment durations for CF patients.